
News|Slideshows|March 31, 2022
American College of Cardiology 71st Scientific Sessions: Science Preview, April 4, 2022
Author(s)Patient Care Editorial Staff
At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.
Advertisement
On the final day of ACC 2022, check out late-breaking clinical trials during 3 different sessions.
A few higlights: Edoxaban vs DAPT post-TAVR, finerenone and cardiorenal outcomes in special CVD populations, canakinumab and residual inflammatory risk, and a report on an international ACC program to improve treatment for STEMI.
Saturday, April 2, 2022 Late Breaking Clincial Trials
Sunday, April 3, 2022 Late Breaking Clincial Trials
More News from ACC on Patient Care
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Estetrol Phase 3 Trial Shows No Impact on Postmenopausal BP, Even in Women at High CV Risk
2
Caroline Mitchell, MD, Describes Toll of Genitourinary Syndrome of Menopause on QoL
3
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
4
Chapter 3: neffy (epinephrine nasal spray)
5









































































































































































































































































































